Temafloxacin: Difference between revisions

Jump to navigation Jump to search
m (Protected "Temafloxacin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Line 1: Line 1:
{{SI}}
{{SI}}
{{EH}}
 


'''Temafloxacin''' (marketed by [[Abbott Laboratories]] as '''Omniflox'''), is a [[fluoroquinolone]] [[antibiotic]] drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths.   
'''Temafloxacin''' (marketed by [[Abbott Laboratories]] as '''Omniflox'''), is a [[fluoroquinolone]] [[antibiotic]] drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths.   
Line 14: Line 14:
[[Category:Fluoroquinolone antibiotics]]
[[Category:Fluoroquinolone antibiotics]]


{{SIB}}
 
{{WH}}
{{WH}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 16:42, 20 August 2012

WikiDoc Resources for Temafloxacin

Articles

Most recent articles on Temafloxacin

Most cited articles on Temafloxacin

Review articles on Temafloxacin

Articles on Temafloxacin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Temafloxacin

Images of Temafloxacin

Photos of Temafloxacin

Podcasts & MP3s on Temafloxacin

Videos on Temafloxacin

Evidence Based Medicine

Cochrane Collaboration on Temafloxacin

Bandolier on Temafloxacin

TRIP on Temafloxacin

Clinical Trials

Ongoing Trials on Temafloxacin at Clinical Trials.gov

Trial results on Temafloxacin

Clinical Trials on Temafloxacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Temafloxacin

NICE Guidance on Temafloxacin

NHS PRODIGY Guidance

FDA on Temafloxacin

CDC on Temafloxacin

Books

Books on Temafloxacin

News

Temafloxacin in the news

Be alerted to news on Temafloxacin

News trends on Temafloxacin

Commentary

Blogs on Temafloxacin

Definitions

Definitions of Temafloxacin

Patient Resources / Community

Patient resources on Temafloxacin

Discussion groups on Temafloxacin

Patient Handouts on Temafloxacin

Directions to Hospitals Treating Temafloxacin

Risk calculators and risk factors for Temafloxacin

Healthcare Provider Resources

Symptoms of Temafloxacin

Causes & Risk Factors for Temafloxacin

Diagnostic studies for Temafloxacin

Treatment of Temafloxacin

Continuing Medical Education (CME)

CME Programs on Temafloxacin

International

Temafloxacin en Espanol

Temafloxacin en Francais

Business

Temafloxacin in the Marketplace

Patents on Temafloxacin

Experimental / Informatics

List of terms related to Temafloxacin


Temafloxacin (marketed by Abbott Laboratories as Omniflox), is a fluoroquinolone antibiotic drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths.

Omniflox was approved to treat lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections in the U.S. by the Food and Drug Administration in January 1992. Severe adverse reactions, including allergic reactions and hemolytic anemia, developed in about fifty patients during the first four months of its use, leading to three patient deaths. Abbott withdrew the drug from sale in June 1992.

External links

Template:QuinoloneAntiBiotics


Template:WH Template:WikiDoc Sources